7 results on '"Hidaka, Tomonori"'
Search Results
2. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan
- Author
-
Kamiunten, Ayako, Shide, Kotaro, Kameda, Takuro, Sekine, Masaaki, Kubuki, Yoko, Ito, Masafumi, Toyama, Takanori, Kawano, Noriaki, Marutsuka, Kousuke, Maeda, Kouichi, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Akizuki, Keiichi, Tahira, Yuki, Shimoda, Haruko, Hidaka, Tomonori, Yamashita, Kiyoshi, Matsuoka, Hitoshi, and Shimoda, Kazuya
- Published
- 2018
- Full Text
- View/download PDF
3. Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma.
- Author
-
Kameda, Takuro, Shide, Kotaro, Tahira, Yuki, Sekine, Masaaki, Sato, Seiichi, Ishizaki, Junzo, Takeuchi, Masanori, Akizuki, Keiichi, Kamiunten, Ayako, Shimoda, Haruko, Toyama, Takanori, Maeda, Kouichi, Yamashita, Kiyoshi, Kawano, Noriaki, Kawano, Hiroshi, Hidaka, Tomonori, Yamaguchi, Hideki, Kubuki, Yoko, Kitanaka, Akira, and Matsuoka, Hitoshi
- Subjects
ADULT T-cell leukemia ,LYMPHOMAS ,BLOOD urea nitrogen ,SURVIVAL rate ,PROGNOSIS - Abstract
A retrospective chart survey of the clinical features of indolent adult T-cell leukemia/lymphoma (ATL) was conducted in the Miyazaki Prefecture, Japan. This study enrolled 24 smoldering-type ATLs, 10 favorable chronic-type ATLs, and 20 unfavorable chronic-type ATLs diagnosed between 2010 and 2018. Among them, 4, 3, and 10 progressed to acute-type ATLs during their clinical course. The median survival time (MST) in smoldering-type ATL and favorable chronic-type ATL was not reached, and their 4-year overall survival (OS) was 73% and 79%, respectively. Compared with this, the prognosis of unfavorable chronic-type ATL was poor. Its MST was 3.32 years, and the 4-year OS was 46% (p = 0.0095). In addition to the three features that determine the unfavorable characteristics of chronic-type ATL, namely, increased lactate dehydrogenase, increased blood urea nitrogen, and decreased albumin, the high-risk category by the indolent ATL-Prognostic Index, which was defined by an increment of soluble interleukin-2 receptor (sIL2-R) of >6000 U/mL, could explain the poor prognosis in indolent ATL patients. The level of sIL-2R might be an indicator of the initiation of therapy for indolent ATL. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T‐cell leukemia/lymphoma.
- Author
-
Sekine, Masaaki, Kameda, Takuro, Shide, Kotaro, Maeda, Kouichi, Toyama, Takanori, Kawano, Noriaki, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Kukita, Toshimasa, Kamiunten, Ayako, Akizuki, Keiichi, Tahira, Yuki, Shimoda, Haruko, Hidaka, Tomonori, Yamashita, Kiyoshi, Matsuoka, Hitoshi, Kitanaka, Akira, and Kubuki, Yoko
- Subjects
ADULT T-cell leukemia ,CANCER chemotherapy ,T-cell lymphoma ,LYMPHOMAS ,PROGNOSIS - Abstract
Objective and Method: Adult T‐cell leukemia/lymphoma (ATL) is an aggressive peripheral T‐cell lymphoma with poor prognosis. We retrospectively reviewed the medical records of 312 patients with aggressive ATL and analyzed the effect of chemotherapy dose intensity on prognosis in clinical practice. Result: As first‐line therapy, 62 patients underwent best supportive care (BSC) or single‐agent chemotherapy, and 235 underwent intensive chemotherapy. The median survival time (MST) was 0.58 years in the 312 total patients, and 0.13 years and 0.75 years in the BSC/single‐agent chemotherapy group and intensive chemotherapy group, respectively. The median average relative dose intensity (ARDI) of patients who received intensive chemotherapy was 60%. We divided patients into 3 groups according to ARDI. Those in the top tertile of ARDI (ARDI ≥ 75%, n = 82) had better overall survival compared with those in the intermediate tertile (45% ≤ ARDI < 75%, n = 79) (P <.0001), with MSTs of 4.69 and 0.75 years, respectively. The occurrence of organ dysfunction and infectious complications was comparable between the two ARDI groups. Conclusion: Higher ARDI improves prognosis in patients with aggressive ATL in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Diffuse large B-cell lymphoma of the gallbladder arised 8 years after malignant lymphoma of the right testis: A case report and literature review.
- Author
-
Kai, Kengo, Hamada, Takeomi, Hiyoshi, Masahide, Imamura, Naoya, Yano, Koichi, Nagano, Motoaki, Kai, Masahiro, Hidaka, Tomonori, Shimoda, Kazuya, Haruyama, Yukihiro, Kataoka, Hiroaki, and Nanashima, Atsushi
- Abstract
• Gallbladder involvement by lymphoma is extremely rare, and only 68 cases have been reported in the English literature so far. • We experienced a case of diffuse large B-cell lymphoma (DLBCL) of the gallbladder arising 8 years after DLBCL of the right testis. • We compiled and analysed reported cases in terms of background, symptoms, imaging findings, and prognosis. • DLBCL was significantly more involved in other organs simultaneously or heterochronously in contrast of MALT lymphoma (p = 0.004). • Gallbladder lymphoma should be added to the differential diagnosis of gallbladder tumours. Gallbladder involvement in lymphoma is extremely rare, and only 68 cases have been reported in the English literature so far. We experienced a case of diffuse large B-cell lymphoma (DLBCL) of the gallbladder arising 8 years after DLBCL of the right testis. A 68-year-old man underwent orchiectomy for malignant lymphoma of the right testis pathologically diagnosed as DLBCL 8 years ago. Systemic surveillance incidentally revealed a gallbladder tumour, and elective resection of the gallbladder bed of the liver was performed under a preoperative diagnosis of gallbladder cancer. The histopathological examination revealed DLBCL. At re-evaluation 3 months after surgery, he was diagnosed as having DLBCL involving the stomach. There had been no recurrence for 39 months after chemotherapy and radiation, but he suffered from a poor general condition due to protein-losing enteropathy and died of infection. We compiled and analysed reported cases of malignant lymphomas involving the gallbladder in terms of background, symptoms, imaging findings, and prognosis. Compared to MALT lymphoma, DLBCL was significantly more involved in other organs simultaneously or heterochronously (p = 0.004). Gallbladder lymphoma should be added to the differential diagnosis of gallbladder tumours, especially when clinical findings are not consistent with the typical course of gallbladder carcinoma and cholecystitis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan.
- Author
-
Hidaka, Tomonori, Shide, Kotaro, Shimoda, Haruko, Kameda, Takurou, Toyama, Keiko, Katayose, Keiko, Kubuki, Youko, Nagata, Kenji, Takenaka, Katsuto, Akashi, Koichi, Okamura, Takashi, Niho, Yoshiyuki, Mizoguchi, Hideaki, Omine, Mitsuhiro, Ozawa, Keiya, Harada, Mine, and Shimoda, Kazuya
- Subjects
- *
CYTOGENETICS , *MYELOFIBROSIS , *MYELOPROLIFERATIVE neoplasms , *PROGNOSIS - Abstract
Cytogenetic abnormalities were often observed in primary myelofibrosis patients. The presence of specific cytogenetic abnormalities, such as sole abnormalities of chromosome 13q−, 20q−, or −7/7q−, is reported to have the influence on the prognosis of primary myelofibrosis. We analyzed the data from the prospective survey of Japanese primary myelofibrosis patients which was conducted from 1999 to clarify the impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis. A total of 202 primary myelofibrosis patients had the cytogenetic and the prognostic data. Eighty (40%) out of 202 cases had cytogenetic abnormalities, and an association was evident for platelet counts. Although the presence of an abnormal karyotype did not affect the prognosis, primary myelofibrosis patients with cytogenetic abnormalities other than 13q− and 20q− showed an inferior prognosis compared to patients with a normal karyotype or sole 13q− or 20q− abnormalities. Patients with an unfavorable cytogenetic profile (abnormal cytogenetics other than 13q− or 20q−) also had a greater tendency to transform to leukemia than patients with a favorable cytogenetic profile (normal cytogenetics, sole abnormalities of either chromosome 13q−, or 20q−). Abnormal cytogenetics other than 13q− or 20q− in primary myelofibrosis patients has the poor prognostic effect for both survival and the risk of leukemic transformation. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
7. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan.
- Author
-
Akizuki, Keiichi, Matsuoka, Hitoshi, Toyama, Takanori, Kamiunten, Ayako, Sekine, Masaaki, Shide, Kotaro, Kameda, Takuro, Kawano, Noriaki, Maeda, Kouichi, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Tahira, Yuki, Shimoda, Haruko, Hidaka, Tomonori, Yamashita, Kiyoshi, Kubuki, Yoko, and Shimoda, Kazuya
- Subjects
MULTIPLE myeloma ,PROGNOSIS ,STEM cell transplantation ,DIAGNOSIS ,MULTIVARIATE analysis ,PLASMACYTOMA - Abstract
The prognosis of multiple myeloma (MM) has improved with the introduction of novel agents. These data are largely derived from clinical trials and might not reflect real-world patient outcomes accurately. We surveyed real-world data from 284 patients newly diagnosed with MM between 2010 and 2018 in Miyazaki Prefecture. The median follow-up period was 32.8 months. The median age at diagnosis was 71 years, with 68% of patients aged >65 years. The International Staging System (ISS) stage at diagnosis was I in 18.4% of patients, II in 34.1%, and III in 47.5%. Bortezomib-containing regimens were preferred as initial treatment; they were used in 147 patients (51.8%). In total, 80% of patients were treated with one or more novel agents (thalidomide, lenalidomide, or bortezomib). Among 228 patients who were treated with novel agents as an initial treatment, the overall response rate (partial response (PR) or better) to initial treatment was 78.4%, and the median time to next treatment (TTNT) was 11.6 months. In the multivariate analysis, PR or better responses to initial treatment were independently favorable prognostic factors for TTNT. The median survival time after initial therapy for patients with novel agents was 56.4 months and 3-year overall survival (OS) was 70.4%. In multivariate analysis, ISS stage I/II disease and PR or better response to initial treatment, and autologous stem cell transplantation (ASCT) were identified as independent prognostic factors for overall survival (OS). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.